Don Kim

Don Kim is recorded as CFO at Canton Strategic Holdings, Inc. (CNTN) since March 27, 2025. Don Kim was last confirmed as CFO at UroGen Pharma Ltd. (URGN) in a filing dated July 15, 2025. Earlier roles on record: CFO at UroGen Pharma Ltd. (URGN) until October 8, 2024. Canton Strategic Holdings, Inc. reported in an 8-K filed June 16, 2025 that Don Kim resigned as Chief Financial Officer, effective June 10, 2025. Canton Strategic Holdings, Inc. reported in an 8-K filed February 27, 2025 that Don Kim was appointed Chief Financial Officer, effective March 27, 2025. UroGen Pharma Ltd. reported in an 8-K filed October 9, 2024 that Don Kim resigned as director, effective October 8, 2024. Equibles holds 5 filed executive changes naming Don Kim; each is listed under recent activity with its source filing. The proxy statement of UroGen Pharma Ltd. reports total compensation of $1,364,222 for Don Kim in fiscal 2024, including a base salary of $363,694. Disclosed compensation is on record for 3 fiscal years. Canton Strategic Holdings, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Canton Strategic Holdings, Inc. includes Mark Wendland (CEO, Chairman and Board Member), Sireesh Appajosyula (CEO and CFO), Vincent LoPriore (Chairman) and 7 others.